期刊
FEMS MICROBIOLOGY REVIEWS
卷 41, 期 3, 页码 323-342出版社
OXFORD UNIV PRESS
DOI: 10.1093/femsre/fux012
关键词
defensins; cathelicidin; antibacterial; antiviral; antifungal; infectious diseases
类别
资金
- Plan Nacional de I+D+i
- Instituto de Salud Carlos III, Subdireccion General de Redes y Centros de Investigacion Cooperativa
- Ministerio de Economia y Competitividad
- Spanish Network for Research in Infectious Diseases - European Development Regional Fund 'A way to achieve Europe' ERDF [REIPI RD12/0015/0001]
- Spanish Adenovirus Network (AdenoNet) [BIO2015-68990-REDT]
- Instituto de Salud Carlos III
- European Development Regional Fund
- Spanish Network for Research in Infectious Diseases [REIPI RD16/0009]
- V Plan Propio de Investigacion of the University of Seville, Spain
Infectious diseases caused by bacteria, viruses or fungi are among the leading causes of death worldwide. The emergence of drug-resistance mechanisms, especially among bacteria, threatens the efficacy of all current antimicrobial agents, some of them already ineffective. As a result, there is an urgent need for new antimicrobial drugs. Host defense antimicrobial peptides (HDPs) are natural occurring and well-conserved peptides of innate immunity, broadly active against Gram-negative and Gram-positive bacteria, viruses and fungi. They also are able to exert immunomodulatory and adjuvant functions by acting as chemotactic for immune cells, and inducing cytokines and chemokines secretion. Moreover, they show low propensity to elicit microbial adaptation, probably because of their non-specific mechanism of action, and are able to neutralize exotoxins and endotoxins. HDPs have the potential to be a great source of novel antimicrobial agents. The goal of this review is to provide an overview of the advances made in the development of human defensins as well as the cathelicidin LL-37 and their derivatives as antimicrobial agents against bacteria, viruses and fungi for clinical use.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据